Boehringer, Gubra stop work on obe­si­ty drug; Gala­pa­gos restarts CAR-T study

Plus, news about Al­ny­lam, Hutchmed, Wave Life Sci­ences and Mati­nas Bio­Phar­ma:

Boehringer In­gel­heim ends work with Gubra on obe­si­ty drug: The Ger­man drug­mak­er

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER